Navigation Links
Bi-Coastal Pharmaceutical Corp. Acquires U.S. Marketing Rights to Aquoral(TM) Artificial Saliva Product
Date:12/11/2008

Exclusive prescription spray product to treat Xerostomia will compete in $1 Billion US Market

RED BANK, N.J., Dec. 11 /PRNewswire/ -- Bi-Coastal Pharmaceutical Corp. announced today that it has acquired the US marketing rights to Aquoral(TM) artificial saliva. Aquoral(TM) is a lipid based artificial saliva spray product that is currently the only Prescription spray product marketed in the United States to treat Xerostomia. The total US market for products treating Xerostomia was estimated at $1 Billion in 2007. The product is sold in a 40ml (1.4 fl. oz.) spray bottle that if used as directed is a 2 month supply. Aquoral(TM) has already received overwhelming acceptance by physicians as well as patients suffering with Xerostomia. The sales and marketing of Aquoral(TM) will begin by Bi-Coastal to the Pharmaceutical trade channels immediately.

Bi-Coastal Pharmaceutical Corp. is a leading Sales, Marketing and Consulting company founded in 1982 and based in Red Bank, New Jersey. Since 2001, Bi-Coastal has secured product sales in excess of $650 Million. Bi-Coastal is currently finalizing its multi-faceted sales and marketing plans for Aquoral(TM) that will include an aggressive trade and physician advertising campaign, telemarketing, direct mail and other programs to physicians as well as a detail sales force initially targeting the Dental, Oncology, Rheumatology and Managed Care markets.

Ralph Massa, Jr., Bi-Coastal Pharmaceutical Corp.'s President and Chief Operating Officer stated the following, "I am pleased to announce the acquisition of Aquoral(TM) and confident that we will achieve significant sales levels well within the first year of marketing the product. Aquoral(TM) will soon be a trusted and proven household name to treat Xerostomia as it is an extremely effective and easy to use product with no known adverse effects. We look forward to the official re-launch of Aquoral(TM) to the trade at the upcoming ECRM conference in Destin, Florida next month as well as discussing many other products that will be a part of Bi-Coastal's exciting product portfolio in 2009."

    For more information please contact:

    Ralph Massa, Jr.
    President and Chief Operating Officer
    Bi-Coastal Pharmaceutical Corp.
    130 Maple Avenue
    Red Bank, New Jersey 07701
    www.bicoastalpharm.com
    Tel-(732) 530-6606 Ext 132
    Fax-(732) 530-1521
    e-mail: rmassa@bicoastalpharm.com


'/>"/>
SOURCE Bi-Coastal Pharmaceutical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AlphaDetail, Inc. Continues Bi-coastal Expansion
2. Employer Vantage From HealthLeaders-InterStudy Provides a Snapshot of Both Self- and Fully-Insured Health Benefits to Help Pharmaceutical and Diagnostic Manufacturers Identify Business Opportunities
3. Napo Pharmaceuticals Announces License of Crofelemer to Salix Pharmaceuticals
4. Synovics Pharmaceuticals Announces Additional Investment by Svizera and Reduction of Debt
5. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
6. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
7. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
8. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
9. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
10. Pharmaceutical Water Markets, the Economic Crunch Creates New Opportunities in Southern and Eastern Europe
11. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... FCPX LUT ... Editors can quickly and easily add washed color grades to footage. A LUT ... LUT changes every pixel’s color to the corresponding color indicated by the table. This ...
(Date:8/21/2017)... ... August 21, 2017 , ... Marathon running has surged ... country. , Outdoor running increases exposure to ultraviolet radiation, a carcinogen that promotes ... melanoma, and only half may be adequately protecting themselves with proper clothing and ...
(Date:8/21/2017)... ... ... PIXACORE , an independent full-service agency with a decade of experience ... year by MM&M. , This is the first time PIXACORE has made the Top ... PIXACORE’s newfound recognition reflects its steady trajectory of growth and recent strategic transformation. ...
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... ... services business of UnitedHealth Group (NYSE: UNH), has made a multi-million dollar partnership ... affected by post-traumatic stress disorder (PTSD) and traumatic brain injuries (TBI) over the ...
(Date:8/20/2017)... ... August 20, 2017 , ... ... HIPAA ComplyPAK™ Compliance Management System has assisted multiple clients in successfully passing ... Accountants, Service Organization Control Level 2 (AICPA SOC Level 2), and State Data ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... 2017 Three Tru-D SmartUVC robots have arrived at ... . Tru-D, short for "Total Room Ultraviolet Disinfection," is a 5-foot-5 ... environmental services (ES) professional cleans the area with traditional cleaning protocols. ... Tru-D fights germs at ... "Although the BAACH has a very low ...
(Date:7/28/2017)... CHICAGO, July 28, 2017 Hill-Rom Holdings, Inc. ... fiscal third quarter ended June 30, 2017, and updated ... For the fiscal third quarter, ... to $0.68 per diluted share in the prior-year period. ... of $0.39 per diluted share primarily related to the ...
(Date:7/27/2017)... Ind., July 27, 2017  Zimmer Biomet Holdings, Inc. ... quarter ended June 30, 2017.  The Company reported second ... 1.1% over the prior year period, and an increase ... 240 basis points of contribution from the LDR Holding ... the second quarter of 2016, or 0.3% on a ...
Breaking Medicine Technology: